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Abstract
GNE myopathy is a rare distal myopathy, caused by mutations in the GNE gene, affecting sialic acid synthesis. Clinical presentation varies from
asymptomatic early stage patients to severely debilitating forms. This first report describes clinical presentations and severity of the disease, using
data of 150 patients collected via the on-line, patient-reported registry component of the GNE Myopathy Disease Monitoring Program (GNEM-
DMP). Disease progression was prospectively analysed, over a 2-year period, using the GNEmyopathy functional activity scale (GNEM-FAS). The
average annual rates of decline in function were estimated at −9.6% and −3.2% in ambulant and non-ambulant patients respectively. 4.3% of
participants became non-ambulant within one year. The mean time from onset to required use of a wheelchair was 11.9 years. Mean delay of
genetic diagnosis from symptom onset was 5.2 years. Mutation specific analysis demonstrated genotype–phenotype relationships; i.e. p.Ala662Val
may be associated with a more severe phenotype, compared to p.Val727Met. Patients with compound heterozygous mutation in epimerase and
kinase domain appeared to have a more severe phenotype compared to patients with both mutations located within one domain. Acknowledging
the limitations of the study, these findings suggest that the severity of the GNE mutations affects disease severity. The GNEM-DMP is a useful data
collection tool, prospectively measuring the progression of GNEmyopathy, which could play an important role in translational and clinical research
and further understanding of genotype–phenotype correlations.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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1. Introduction
GNE myopathy has been originally described under several
names: hereditary inclusion body myopathy (HIBM), distal
myopathy with rimmed vacuoles (DMRV), quadriceps sparing
myopathy (QSM) and Nonaka disease-reflecting clinical and
biopsy presentation, genetic cause and history of discovery
[1,2]. It is a rare autosomal recessive myopathy caused by
bi-allelic mutations in the GNE gene (UDP-N-acetyl-2-
epimerase/N-acetylmannosamine kinase). Recently, GNE
myopathy is the agreed term to name the condition, and the
longest transcript of the GNE gene (hGNE2) is used for variant
and mutation annotation [3].
The estimated prevalence varies between countries. The
highest rates are reported in the Persian Jewish community [4],
Japan (0.3), UK and Northern Ireland (0.44) [5] per 100,000,
and in the Roma population in Bulgaria (incidence 1 in
500 births) [6]. Based on allele frequencies in three exome
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sequence databases, the global prevalence has been estimated at
0.4–2.1 per 100,000 [7].
The presentation and clinical course of GNE myopathy have
been illustrated in several case reports and small cohort studies,
most of them limited to a single centre or a particular country.
The onset of GNE myopathy usually occurs in the third decade
of life, but earlier and later appearances have been reported. It
presents as a lower extremity distal myopathy that progresses
proximally with relative sparing of the quadriceps muscle of
the thigh. Upper limbs involvement occurs in parallel with the
proximal leg musculature progression. The diagnosis is usually
based on the pattern of muscle weakness, modest elevation of
serum creatine kinase (CK) level, and a muscle biopsy showing
rimmed vacuoles (on either H&E or Gomori’s trichrome stain),
and tubulofilamentous inclusions without evidence of
inflammation [8]. Identification of mutations in both alleles of
the GNE gene is critical for diagnostic confirmation of GNE
myopathy. Several observational studies suggest that progression
of the disease is steady and relatively slow, but ultimately leads
to loss of ambulation within 10–20 years from the onset of
first clinical symptoms [9–12].
There is currently no approved treatment for this
disease, but attempts are being made to supplement sialic
acid deficiency with oral aceneuramic acid slow release
[13] (www.clinicaltrials.gov ID number NCT02731690,
NCT02736188, NCT01517880, NCT01830972, NCT01236898).
Currently, a phase 3 study is underway (NCT02377921). Sialic
acid precursor – N-acetyl-D-mannosamine (ManNAC) presents
another promising therapeutic option. For the latter type of
treatment, a Phase 1 trial (NCT01634750) is complete and a
Phase 2 trial (NCT02346461) is currently ongoing). A single
attempt of gene therapy in a patient was documented in 2011
[14].
Over 150 mutations scattered across the GNE gene
have been reported to date [7]. Of these mutations, several
were identified as founder or recurrent mutations [4–6,
15,16], but many are sporadic and/or found in single families
only.
Genotype–phenotype studies suggest that certain point
mutations are linked to age at onset, presenting symptoms,
severity and speed of the disease progression [10,16]. The
largest genotype–phenotype correlation study (n = 212) suggests
that one of the most common mutations in Japan p. Asp207Val
predisposes to later onset and milder phenotype as opposed to
p.Val603Leu [9]. However, phenotype analysis in patients
homozygous for the same mutation suggested significant inter-
and intra- familial variability [6]. The Japanese study suggested
phenotype difference between homozygous and compound
heterozygous carriers [9]. No patient has so far been identified
as carrying two nonsense or frameshifting mutations, suggesting
that some basic activity of GNE is required during early
development.
In this paper we describe the international online GNE
myopathy Disease Monitoring Program (DMP) patient registry,
which collects patient self-reported data from around the world.
The registry collects medical and quality of life information
reported by patients and is augmented by genetic and biopsy
reports. The registry aims to contribute to a better recording of
the disease course, its diversity and possible genotype–
phenotype correlation.
2. Materials and methods
TREAT-NMD and Ultragenyx Pharmaceutical Inc. (Novato,
CA, USA) established a public-private partnership in 2012 to
conduct a GNE myopathy DMP linking two data collection
efforts (Fig. 1). The study consists of two components: an
international online registry with data entered by patients and a
separate hospital based observational study with data entered
by site staff per typical clinical research methods. The online
DMP aims to acquire information on medical and diagnostic
history, clinical symptoms and the progression of the disease
from GNE myopathy patients worldwide. The study received
full ethical approval from UK NRES Committee North
East – Newcastle and North Tyneside 1 in 2013 (approval ID
13/NE/0123. ClinicalTrials.gov Identifier: NCT01784679). All
Fig. 1. GNE Disease Monitoring Program study design. International patient self-reported registry run alongside the hospital based natural history study. Registry
data set is governed by the Steering Committee and can be accessed via enquiries by the clinical and scientific community.
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participants have consented prior to their participation in the
study.
2.1. Online registry design
The registry www.gnem-dmp.com was set up as a
patient self-reported online database for patients clinically
diagnosed or genetically confirmed with GNE myopathy.
Patient participation is not restricted to any specific geographic
location. All participants have been provided with patient
information and a consent form. Patients were also encouraged
to contact the registry curator at Newcastle University, their
doctor or patient advocacy groups if they had any questions.
Participants can sign the consent form electronically or use hard
copies. The signed consent form allows the registry curator to
contact the participant for future data validation, research and
communication purposes. It also allows the registry curator to
contact the doctor they nominate in order to request missing
information and the validation of participant entered data. No
protected health information is shared with the corporate
sponsor. After informed consent has been obtained participants
are asked to complete a set of validated 12-item short form
survey (SF12), GNEM-FAS and non-validated questionnaires
that are similar (where applicable), to the natural history study
data set, to describe their medical history, level of activity, use
of assistive devices and quality of life. Participants can upload
their laboratory test results including muscle biopsies, genetic
reports and general medical documentation to the registry. The
registry has been online since 1 March 2014 and will continue
to enrol and follow patients over time.
2.2. Interval history data collection
Patients are encouraged to log in to the registry at 6-month,
12-month and then annual intervals in order to update their
profile and report any changes in their medical history, activity
level or quality of life.
2.3. Database platform
The original database platform (1 March 2014–30 October
2015) was split between two vendors. Summit Analytical LLS
(Denver, USA) holding de-identified participant data, and
Orchid Inc. (Washington, USA) holding data, which is
identifiable. The data was subsequently migrated to the current
database platform, Digital Infuzion (Maryland, USA). The
database platform consists of a participant facing front-end
where consent and questionnaire forms are completed and a
back-end, designed for use by the registry curator to review and
manage entered data.
2.4. Patient recruitment
The registry was promoted via the dissemination of
information on www.clinicaltrials.gov, neuromuscular and rare
disease networks (e.g. TREAT-NMD, Orphanet) and patient
organisations (e.g. Muscular Dystrophy UK (MD UK) and
Neuromuscular Disease Foundation (NDF) (USA). Information
about the registry was also included in genetic reports
confirming GNE myopathy issued by the Northern Genetic
service (UK). When registering, patients provide their names
and consents for participation in the registry and for contact
by registry curator with Newsletters and other relevant
information.
2.5. Data management
The data collection follows EU data protection directive
95/46/EC. The registry is curated by TREAT-NMD. Data
entered into the registry is stored securely on databases
managed by Digital Infuzion, where access to the data set is
limited to named individuals at Newcastle University and
Digital Infuzion. Study principal investigator, registry curator
and team involved in the platform development have access to
the complete data set including identifiable data. No identifiable
data are available to other study team members or to the
corporate sponsor. The registry curator verifies all entered data
via medical documentation provided by the participant, or
alternatively by contacting the clinician nominated by the
participant (upon participants’ consent). Participants are able to
withdraw their consent and entered data in the registry at any
time.
2.6. Information governance and third party enquiries
A steering committee, with a defined charter and
representation from public, private and academic sectors was
established in 2014. It consists of seven members: 2 from
TREAT-NMD, 2 international academic experts, 1 from
Neuromuscular Disease Foundation, and 2 from Ultragenyx.
The Steering Committee has strategic input and ensures that the
registry is functioning in the patients’ best interests. Third
parties (e.g. researchers) may place an enquiry for access to the
dataset to ask specific questions. The Steering Committee
makes a decision about the request. In cases where the decision
is positive, researchers may need to seek ethical and other
relevant approvals, before receiving a report or other service
from the registry.
2.7. Data analysis
The data analysed for this report was collected between 1
March 2014 and 1 October 2016. The data was checked for
consistency and quality. Where necessary, the registry curator
contacted patients to clarify entered data. The data entered in
the registry by patients were augmented by the genetic and
biopsy reports provided by the patients. Data analysis was
performed using SPSS statistics version 22. Descriptive
statistics and mean values with 95% CI are presented where
applicable. Linear regression analysis, ANOVA, and Chi square
test were used to test for an association among GNEM-FAS
score, medical history parameters and genotype. Linear
regression analysis was used to test for an association between
GNEM-FAS score and duration of the disease.
3. Results
Between 1 March 2014 and 1 October 2016 (31 months) 269
participants registered with the www.gnem-dmp.com.
The monthly rate was between 1 and 19 (average n = 7)
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registrations. Five newsletters were distributed to the patients.
Newsletters supported the recruitment into a clinical trial, a
natural history study, and two patient advocacy meetings.
Newsletter recipients appreciated the information provided in
their native language; they benefitted from specific content of
the newsletters, related to medical and social aspects of
the disease. Participants were very proactive in suggesting
discussion points for the newsletters and in sharing their life
stories.We have conducted a survey asking registry participants
about their experience in completing the questionnaires,
navigating the website and registry curator support. The survey
showed that patients were satisfied with their experience. The
newsletters were also distributed via the TREAT-NMD network
and increased awareness among healthcare professionals.
Several patient organisations and support groups were
popularised via the newsletter and in turn provided articles and
content to the newsletters.
The registry assisted with the identification of subjects in the
GNE natural history study (NCT01784679) and Phase 3
clinical trial (NCT02377921). One hundred and fifty patients
completed the questionnaires and were included in the analysis.
The registry curator has followed up with all patients to clean
the data and minimise the amount of missing data.
3.1. Baseline demographics
Registry participants represent 26 countries (Supplement
Fig. S1). The following countries contributed the largest
number of patients: Iran, Italy, South Korea, USA, UK, and
India together represent 77.7% (n = 115) of all patients that
answered questionnaires. Male and female participants
constitute similar proportions (male n = 72, 48%, female
n = 78, 52%). Mean age at baseline and body mass index (BMI)
were as follows: male mean age = 38.7 [range 19–70 years],
BMI = 25.9 kg/m2, female mean age = 39.5 [range 20–74
years], BMI = 23.5 kg/m2 Breakdown of age groups is shown in
Supplement Fig. S2.
The breakdown of ethnical background: White n = 85
(56.6%); Asian n = 54 (36.6%), Black African n = 1 (0.7%),
Mixed n = 4 (2.7%), “I do not want to disclose” n = 6 (4%).
HIBM is the most commonly used name (58.7% of the cases),
followed by GNE myopathy (25.4%), DMRV (8.7%), Nonaka
disease (5.1%), LGMD (0.7%, confirmed GNE mutations).
Fourteen families have several siblings (between 1 and 7)
affected by GNE myopathy. One to three siblings from each
family signed up to the registry. This constitutes 30% of all
registry participants.
3.2. Onset, progression and diagnosis
Onset and first symptoms were recorded predominantly
between 20 and 40 years (84.8%). Mean age of onset was at
27.8 years (95% CI 26.6–29.0. range 15–50 years old). Women
had an earlier onset than men: female mean age = 26.5 years
(95% CI 24.9–28.2), male mean age = 29.2 years (95%CI
27.5–30.1), p = 0.027. The earliest subclinical presentation was
described as a “slow runner since 3 years old”. Early onset (<20
years) was observed in 11.4% of patients, late onset (>40 years)
in 3.8%. The latest onset was observed in 1 patient at 50 years
of age.
Symptoms reflecting lower extremity weakness presented in
most of the patients (Fig. 2a) (mean age 28.8 years). Difficulty
lifting toes was experienced by 93.3%, weakness in legs and
feet by 97.0%, difficulty walking by 97.8%, frequent falls or
stumbles by 90.2%, difficulty climbing stairs by 93.2% of the
respondents (Fig. 2b).
Weakness in arms and hands was reported in 90.3% of
patients (Fig. 2c), on average starting 4 years later (32.8 years)
than lower extremity symptoms. Difficulty sitting unaided
(without any support) and changing position (i.e. turning in
bed) were reported in 22.4% and 79.1% of respondents
(Fig. 2d) at average age of 34.0 and 33.7 years respectively.
Feeling fatigued was a common complaint (89.6%), as well as
muscle spasms or twitching (59.7%) and muscle pain (45.9%).
3.3. Use of assistive devices and ambulation status
Non-ambulatory status was assigned to patients who cannot
walk a short distance within the house and who use the
wheelchair all the time. Non-ambulant patients at baseline
constitute 24.3% of the registry population.
Ankle-foot orthoses (AFO) were used by 41% (n = 57) of
respondents, a small number of patients were using high top
boots 2.1% (n = 3) and shoe inserts 7.2% (n = 10). As displayed
in Table 1, on average patients start to use AFOs at the age of
33.0 years (95% CI 30.8–35.3), a few years after the average
age for first lower extremity symptoms.
Approximately 3 years later, at a mean age 36.3 years
(95% CI 33.5–39.1) some patients (41%) start using assistive
devices to help them walk. A cane was used by 22% of all
respondents, crutch by 6.2%, and walker by 17.4%.
Wheelchair or scooters were used (36.4% of all respondents)
by non-ambulant patients and by the weaker ambulant patients
for longer journeys (e.g. travels through the airport or
shopping). First use of a wheelchair was reported at a mean age
of 38.3 years (95% CI 35.5–41.1). On average it took 11.9 years
from the onset until a wheelchair is required (95% CI 10.2–
13.5), [range 5–25 years].
3.4. Genotype analysis and genotype–phenotype observations
To calculate the age at diagnosis we used the date of the
genetic report confirming GNE mutations. Mean age at
diagnosis was 32.7 years (95% CI 31.0–34.5) in the subset of
patients (n = 93) with available genetic reports. The time gap
between the reported onset of the disease and diagnosis
averaged 5.2 years (95% CI 3.0–7.4 years), [0–29 years].
Review of genetic reports showed that both nomenclatures
(hGNE1 and hGNE2) are in use by the laboratories in various
countries. Mutations in the GNE gene were detected in exons
2–12, but not in exon 1 and 8 (Fig. 3).
A wide range of mutations was identified. Most of the
mutations (50/58) are missense; other mutations were: 1
nonsense, 1 frame shift, 3 deletions, 1 large deletion, 1
duplication and 1 deletion/insertion. Six of the most common
mutations accounted for over 60% of all alleles observed in the
ARTICLE IN PRESS
Please cite this article in press as: Oksana Pogoryelova, et al., Phenotypic stratification and genotype–phenotype correlation in a heterogeneous, international cohort of GNE myopathy
patients: First report from the GNE myopathy Disease Monitoring Program, registry portion, Neuromuscular Disorders (2017), doi: 10.1016/j.nmd.2017.11.001
4 O. Pogoryelova et al. /Neuromuscular Disorders ■■ (2017) ■■–■■
registry population (Table 2). A complete list of mutations is
shown in Table S1 of supplementary materials.
Genotype–phenotype observations were analysed by domain
and specific types of mutations as follows:
1. Patient reported outcomes were compared among three
categories: A. two mutations in the epimerase domain, B.
one mutation in the epimerase and kinase domain, C. two
mutations in the kinase domain (Table 3).
Fig. 2. Cumulative percent of age of symptom appearance. A. Lower extremity difficulty. B. Mobility difficulties C. Upper extremity weakness D. Difficulty
changing position.
Table 1
Estimated timeline of main milestones including disease onset and progression,
and age at diagnosis.
Criteria Mean years (SD) Mean years since
the onset (SD)
Age at onset 27.8 (7.0) –
Lower extremity weakness 28.8 (6.7) 1.2 (3.6)
Age at diagnosis 32.7 (9.5) 5.2 (10.9)
Upper extremity weakness 32.8 (8.7) 5.2 (5.2)
Use of AFO 33.0 (7.7) 4.8 (5.7)
Difficulty sitting unaided 34.0 (9.0) 7.9 (5.6)
First use of wheelchair 38.3 (9.5) 11.9 (6.1)
Fig. 3. Mutation distribution by exon and kinase or epimerase domain.
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2. Patient reported outcomes were compared between
homozygous and heterozygous carriers of the 4 most
common mutations (p.Met743Thr; p.Ala662Val;
p.Val727Met; p.Arg277Trp) where number of patients was
n > 15; Patients carrying two heterozygous mutations from
the selected list of mutations were excluded from the
analysis.
Selected outcome parameters include: age at onset, age at
first wheelchair use, percent of non-ambulant patients in the
analysed group, total GNEM-FAS score at baseline. The age
distributions between all subgroups (by domain and by specific
mutations) are comparable. However, the gender proportions
vary substantially between subgroups (Table 3).
The difference in outcome measures between the groups was
not statistically significant, but a trend was observed. Patients
with one mutation in each domain (group B) had the lowest
proportion of ambulant patients, earliest onset and earliest first
use of wheelchair, compared to patients having both mutations
in either epimerase or kinase domain.
Analysis of outcomes between specific genotypes is
presented in Table 3 with statistically significant differences
marked. There were a few general trends observed. Genotype
p.Val727Met appears to have a milder phenotype with no non-
ambulant patients to date, later onset, highest GNEM-FAS
score and latest age of first wheelchair use.
Genotype p.Ala662Val group has the lowest proportion of
ambulant patients and lowest GNEM-FAS score which might
partially be explained by the fact that this group is the oldest in
this data set.
Genotype p.Arg277Trp and p.Val727Met group have similar
age at study baseline, however the p.Arg277Trp has 20.0% less
ambulant patients and much lower (24.8%) GNEM-FAS score,
which may indicate that this genotype predisposes to a more
severe phenotype.
3.5. Muscle biopsy reports analysis
Most of the patients (86.9%) have had a muscle biopsy.
Fifty-two biopsy reports were made available for review. Most
common muscle biopsy sites were Tibialis anterior, Biceps
brachii, Deltoid, Quadriceps (unspecified), Gastrocnemius,
Gluteus maximus, Rectus femoris, Peroneus longus, hamstring
(unspecified), and other unspecified muscles. The most
common presentation is described as a myopathic or neurogenic
pattern with rimmed vacuoles. The following findings of
characteristics of a myopathy were observed: fibre size
variation, fibre necrosis and regeneration and internalised
nuclei. The following signs indicating a neurogenic component
were observed: angulated fibres, clumped nuclei, and grouping
of fibres. The abundance of rimmed vacuoles correlates with
the stage of the disease (more vacuoles in more affected
Table 2
List of most common mutations.
Nucleotide change Amino acid change Number of patients, n = % Most common country of origin Country of origin (other)
c.2228T > C p.Met743Thr 37 20.2 Iran Saudi Arabia, Italy, USA
c.1985C>T p.Ala662Val 19 10.4 UK USA, Ireland
c.2179G>A p.Val727Met 17 9.3 India Bangladesh, UK, Germany, Guyana, USA
c.829C>T p.Arg277Trp 16 8.7 Iran Moldova, India, UK
c.1807G>C p.Val603Leu 12 6.6 South Korea
c.1225G>T p.Asp409Tyr 9 4.9 UK
Total 110 60.1
Table 3
Genotype–phenotype correlation analysis. Baseline demographics and outcome factors analysed by the mutation location (epimerase, kinase or both). Also 4 most
common mutations are included in the analysis.
Fixed factors, cohort description Outcome factors
Genotype Age at baseline,
mean (95% CI)
Sex,
F%/M%
% of
ambulant
patients
Mean age
of onset (95% CI)
Mean GNEM-FAS
score, total %
(95% CI)*
Mean age
of first use
of wheelchair
By domain (A) Epimerase [exon 1–7], n = 18 40.2 (35.3–45.2) 72/28 82.3 29.2 (24.8–33.5) 51.1 (37.0–65.2) 44.5
(B) One epimerase, one kinase, n = 30 39.8 (36.1–43.8) 50/50 70.0 26.2 (23.5–28.9) 52.1 (41.7–62.5) 38.6
(C) Kinase [exon 8–12], n = 41 40.4 (36.7–44.1) 46/54 82.1 29.7 (27.7–31.7) 62.9 (55.6–70.2) 41.5
By mutation p.Met743Thr n = 20 (homozygous- 85%) 40.4 (35.3–45.5) 40/60 84.2 27.8 (25.0–30.7) 61.4 (50.8–72.0) 43.2
p.Ala662Val, n = 15 (homozygous- 33%) 48.1 (42.3–53.9) 67/33 60.0 30.8 (26.5–35.1) 41.8‡ (27.7–55.9) 43.1
p.Val727Met, n = 12 (homozygous- 8%) 39.2 (33.2–45.1) 42/58 100 30.8 (26.9–34.6) 77.8 (69.0–86.6) 46
p.Arg277Trp, n = 11 (homozygous- 64%) 39.3 (33.0–45.6) 73/27 80.0 29.2 (24.5–34.0) 53.0 (33.1–72.3) 42
Other (not carrying mutations above), n = 23 35.3† (30.1–40.0) 48/52 82.6 25.7 (22.3–29.4) 56.3 (44.1–68.5) 33
* Three domains of FAS questionnaire. Score calculated as % normal functionality (100%), which means no limitations in the mobility, upper extremity and
self-care function.
† Age at baseline statistically different between p.Ala662Val and “other” group, p = 0.003.
‡ ANOVA test of GNEM-FAS score between p.Ala662Val and p.Val727Met group p = 0.002.
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muscles) and the site of biopsy. The most affected muscle, e.g.
Tibialis anterior, is affected at early stages of the disease and
shows multiple rimmed vacuoles. Quadriceps however is
spared until late stages and does not tend to exhibit rimmed
vacuoles. Inflammatory findings and normal biopsy were noted
on 2 and 1 occasions, respectively. Immunohistochemistry
analysis showed no protein deficiency.
3.6. Longitudinal data analysis
To assess longitudinal changes we asked registry
participants to complete medical history and GNEM-FAS
questionnaires at 6-month, 12-month and 24-month time
points. One patient (2%) became non-ambulant in the
first 12 months of observation. The GNEM-FAS extended
questionnaire (which includes extra questions appropriate for
patients with significant mobility impairment) was analysed by
domain: mobility, upper extremity, self-care and a total score
(sum of scores in all three domains). The GNEM-FAS extended
questionnaire has 30 questions, with answers rating from 0
(unable to do) to 4 (having no difficulty to do). Each score is
weighted equally. The data is presented in the table in two
forms: score and percent of a maximum achievable score
(100% or normal functional level corresponds to 120 points on
the total scale). Data from ambulant (Fig. 4) and non-ambulant
(Fig. 5) patients were analysed separately due to the difference
in physical ability. Clear functional decline in ambulant patient
was observed at all three FAS domains over 2 years. The ability
to move (e.g. walk, frequent falls or stumbles, weakness in legs)
saw the greatest reduction in functionality, with on average
57.8% of normal functionality preserved. Over two years, the
FAS score for the mobility domain dropped by 17.8%. Upper
extremity function and self-care were both better preserved
with 78.9% and 79.4% of normal function respectively at
baseline. However, we observed a significant decline in both
domains by 19.2% and 26.4% respectively over 2 years.
Non-ambulant patients were significantly weaker with 15%
of mobility preserved. Similar to the ambulant group, upper
extremity and self-care function were better preserved with
34.3 and 33.8%, respectively at baseline. There was a decline in
function across all domains in the first year, however year 2 data
analysis showed only a slight increase in FAS score across all 3
domains. Only 6 non-ambulant patients reported GNEM-FAS
scores at the 24-month time point, so the small number of
observations may potentially introduce bias. The speed of
functional decline in ambulant patients was slower than in non-
ambulant patients (Table 4). Analysis of GNEM-FAS score in a
subset of patients who completed all four visits over 2 years
showed steady and statistically significant decline.
The overview of the GNEM-FAS score in the whole cohort
shows a linear negative correlation between duration of the
symptomatic period and GNEM-FAS score (beta = −0.475,
p < 0.001) (Fig. 6). A slight increase of GNEM-FAS score in a
group of >15 years duration, also has higher CI, reflects a
smaller sample size. As expected, patients with a longer history
of the disease are weaker. This may suggest that patients with a
longer duration of the disease, regardless of their actual age, are
in a greater need of technical and social help in their daily
activities and therefore have a greater impact on costs of disease
health economics.
3.7. Other concomitant conditions and diseases
3.7.1. Depression
Patients with clinically diagnosed depression and those
receiving treatment for depression, totalled 9.5% (13/137) of
registry participants included in analysis. Based on the SF12
questionnaire, and health and wellbeing questionnaires, 13.0 to
Fig. 4. GNEM-FAS extended questionnaire analysis over 2 years in ambulant patients. Three domains of GNEM-FAS extended: mobility, upper extremity function
and self-care analysed separately alongside the total FAS score.
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19.3% of respondents feel low and depressed most or all of the
time respectively.
3.7.2. Pain
A significant number of patients experienced
musculoskeletal pain (45.9%). The most common location of
pain was legs (32.6% of all respondents), then arms and hands
(10.5%), back (9.8%), shoulders (9.0%), and neck (4.5%).
3.7.3. Cardiovascular and respiratory involvement
In medical history analysis we focused on conditions related
to the cardiovascular and respiratory system.
Thirteen respondents (9.5%) reported that they have a
cardiovascular condition. The diagnosis was reported as
follows; cardiomyopathy (treated with medication) – 1.5%
(2/137), high blood pressure – 5.8%, palpitations and
tachyarrhythmia – 1.5%, deep vein thrombosis – 4.5%, on
Fig. 5. GNEM-FAS extended questionnaire analysis over 2 years in non-ambulant patients. Three domains of GNEM-FAS: mobility, upper extremity function and
self-care analysed separately alongside the total FAS score.
Table 4 A
Functional activity scale (FAS) analysis. FAS domains (mobility, upper extremity and self-care) are analysed in ambulant (A) and non-ambulant (B) cohorts
separately. The data presented as mean score with 95% CI and mean % of maximum achievable score/function with 95% CI.
A
Ambulant
Baseline, n = 98 6 months, n = 27 12 months, n = 41 24 months, n = 16
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
Mobility Score 30.0 (27.8–32.3) 29.9 (26.5–33.2) 27.1 (24.1–30.1) 20.8 (15.7–30.0)
% 57.8 (53.5–62.0) 57.4 (50.9–63.9) 52.1 (46.3–57.9) 40.0 (30.1–50.0)
Upper extremity Score 28.4 (27.0–29.7) 28.9 (26.6–31.2) 26.5 (24.1–29.0) 21.5 (16.7–26.4)
% 78.9 (75.1–82.6) 80.3 (73.8–86.7) 73.7 (67.0–80.4) 59.7 (46.2–73.2)
Self-care Score 25.4 (24.3–26.5) 25.6 (23.5–27.6) 23.4 (21.1–25.4) 18.6 (15.5–21.6)
% 79.4 (76.0–82.8) 79.9 (73.5–86.3) 72.6 (66.0–79.3) 53.0 (48.4–67.6)
Total Score 83.8 (79.7–88.0) 84.3 (78.1–90.5) 76.9 (70.6–83.1) 60.9 (49.8–72.0)
% 69.9 (66.4–73.3) 70.3 (65.1–75.4) 64.1 (58.9–69.2) 50.7 (41.5–60.0)
Table 4 B
Functional activity scale (FAS) analysis. FAS domains (mobility, upper extremity and self-care) are analysed in ambulant (A) and non-ambulant (B) cohorts
separately. The data presented as mean score with 95% CI and mean % of maximum achievable score/function with 95% CI.
B
Non-Ambulant
Baseline, n = 34 6 months, n = 11 12 months, n = 13 24 months, n = 6
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
Mobility Score 7.9 (5.0–10.7) 7.1 (1.4–12.8) 6.1 (2.3–10.0) 6.7 (1.5–14.8)
% 15.1 (9.6–20.6) 13.6 (2.7–24.6) 11.8 (4.4–19.3) 12.8 (2.8–28.4)
Upper extremity Score 12.4 (9.4–15.4) 10.0 (4.3–15.7) 7.5 (3.2–11.7) 8.0 (2.1–13.9)
% 34.3 (26.0–42.6) 27.8 (11.9–43.7) 20.7 (9.0–32.5) 22.2 (5.7–38.7)
Self-care Score 10.8 (8.1–13.5) 10.0 (4.3–15.7) 7.5 (4.1–11.0) 8.8 (2.0–15.7)
% 33.8 (25.3–42.3) 31.3 (13.5–49.0) 23.6 (12.8–34.3) 27.6 (6.3–48.9)
Total Score 31.0 (22.8–39.2) 27.1 (10.6–43.6) 21.2 (10.4–31.9) 23.5 (3.7–43.3)
% 25.9 (19.0–32.7) 22.6 (8.8–36.3) 17.6 (8.6–26.6) 19.6 (3.1–36.1)
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warfarin treatment (unspecified) – 0.7%, mildly impaired left
ventricular systolic function – 0.7%.
Respiratory difficulties (“difficulty breathing”) were noted
by 10.2% (n = 14). Four patients have asthma (2.9%), in 4
patients difficulty in breathing was associated with
cardiovascular conditions (arrhythmia, palpitations, HBP, and
cardiomyopathy) and 2 of them use CPAP for an unspecified
reason. Four other patients reported breathing difficulties due to
anxiety (n = 1) or other unspecified reasons (n = 3).
4. Discussion
Rare and ultra-rare diseases often reveal gaps in understanding
disease diversity, its characteristics and disease modifying
factors due to the small number of observed patients. Most of
the knowledge currently available on GNE myopathy are
derived from case reports or local (they were not too small
compared to this study) cohort observations. Patient registries,
although subject to the natural bias of patient-reported data,
have proven useful in longitudinal observational data collection,
establishing a pool of patients for clinical trial readiness and
contributing to an overall better understanding of rare diseases
[17,18]. Specifically, the Japanese national GNE registry Remudy
has provided valuable insights into the demographic, medical
history and correlation between phenotype and genotype on
the largest number of GNE myopathy patients in one country
[19,20]. To our knowledge, there are no other national GNE
specific registries.
Rare diseases impose specific challenges in clinical research
due to small sample size and heterogeneity of the disease
course. Therefore, clinical research into rare diseases including
GNE myopathy often requires coordinated, multicentre,
international collaboration in order to combine effort and
knowledge under one roof in a standardised process. We have
addressed these challenges by setting up a centralised,
international registry as part of the GNE myopathy Disease
Monitoring Program (DMP). The private-public partnership
coinciding with the oversight from the international Steering
Committee has successfully ensured meaningful, secure and
sustainable data collection via the online registry platform.
The registry or online portion of the GNEM-DMP is a
valuable tool in delivering relevant medical and scientific
information to the participants. Newsletters translated in to a
wide range of languages have provided an opportunity to
engage with participants internationally, giving them the
opportunity to also participate by writing their own articles for
inclusion. The registry has also assisted in recruitment to
clinical research activities, surveys and patient advocacy
meetings.
Genetic basis for GNE myopathy was established relatively
recently with the causative gene discovered in 2001 [21].
Geographical distribution of the cases in the GNE registry
shows the global representation of GNE myopathy with similar
proportion of men and women affected. However, the women
enrolled in the registry tend to have an earlier onset on
average than men, which has not been previously reported. A
possible explanation could be that there is an aggravating
effect of pregnancy on muscle strength in general and
possibly by increased requirement of Sialic acid during pregnancy
[22].
Although GNEmyopathy has a distinct clinical presentation,
it is important to confirm the diagnosis genetically and to
exclude other distal myopathies with similar presentation for a
correct care and disease management. Registry participants
reported on a wide range of diagnostic delays between onset of
the disease and genetic confirmation (between months and
decades). Recently, GNE genetic testing became more widely
available which reduced the waiting times for patients.
The presented timeline of the disease milestones confirms
the slow, but progressive course and a noticeable variability
between patients even with the same genotype [8,9,23,24].
The early requirement for the use of orthotics may reflect the
specific pattern of muscle weakness, e.g. distal leg involvement
(foot drop). Individual progression from the onset of first
symptoms to the wheelchair use stage is variable and could be
linked to specific GNE genotype and other yet undiscovered
modifiers. Also it may represent the local financial support for
wheelchair supply.
To measure the actual decline of the function we used the
patient reported outcome measure- the GNEM-FAS questionnaire,
specifically designed for GNE myopathy and used in clinical
research and trials [25]. For this report, measurable decline
was determined at 4 time points over 2 years in ambulant and
non-ambulant cohorts (Fig. 7). The most affected item is mobility
and the most preserved is upper extremity function. This is
consistent with a natural history study conducted in Japan in
ambulant and non-ambulant patients, where physical outcome
measures were used [26].
The decline over 2 years was similar across three GNEM-
FAS domains in ambulant patients. Non-ambulant patients have
much lower baseline GNEM-FAS score and slower decline of
the remaining muscle function, however measurable decline
Fig. 6. GNEM-FAS extended analysis by years since the onset.
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was also observed and could serve as an important baseline
marker for efficacy assessments of the new therapies. This is in
line with the natural history studies [26,27].
Observed relationships between genotype and self-reported
clinical parameters indicate that the severity of the disease
might be partially attributable to the specific GNE genotype. In
our study, patients with bi-allelic mutations in both the
epimerase and kinase domains were predisposed to a more
severe phenotype compared to the patients with both mutations
located in just one domain. This could partially be attributable
to the fact that mutation that is expected to cause more severe
phenotype was prevalent in the epimerase and kinase groups.
This observation is in contrast with findings in 35 Chinese
patients with GNE myopathy, which suggested that mutations
in the epimerase domain may lead to atypical clinical
presentation and later onset compared to the patients with both
mutations in the kinase domain [16]. In that cohort, Chinese
patients carried the milder D207V mutation. As a result, the
domain-specific analysis could be obscured by the mutations.
Moreover, this study had a smaller sample size from one ethnic
group only; therefore the results are not fully comparable and
may not easily be extrapolated to other ethnicities and
countries. The molecular mechanisms underlying genotype–
phenotype correlations are yet to be elucidated and may involve
a GNE protein function other than sialic acid synthesis.
Limitations in our study include reliance on patient reported
information and potential for bias given the voluntary nature of
patient’s participation in the GNEM-DMP on-line registry.
Our data taken together with a literature review suggest that
within one domain, GNE mutations could result in a severe and
mild mutations depending on the dominating mutation in the
analysed cohort.
Detailed analysis of individual, highly prevalent mutations
showed that the mutation p.Ala662Val (UK) may predispose to
a more severe phenotype than the mutation p.Val727Met (India)
p.Ala662Val demonstrating with an earlier onset and faster
progression of the symptoms. Similarly, a difference between
two Japanese founder mutations was previously described [24].
Comparative analysis of enzyme activity in heterologous
systems modelling different GNE mutations supports the
hypothesis that the mutations are not identical in their effect on
protein stability and enzyme activity [28]. Therefore, it is
important to consider individual trajectories and potential
genotype–phenotype correlations for patient stratification in
clinical trials and for clinical management.
GNE myopathy does not appear to be associated with an
increased risk of cardiomyopathy, CVD or respiratory failure
[12], however respiratory difficulty is observed in advanced
stages of the disease [24]. Our initial data do not suggest an
increased risk of respiratory difficulty, in GNE patients in
comparison to the general adult population. Dilated
cardiomyopathy and cardiac conduction abnormalities, and sudden
death have been reported in GNE myopathy occasionally [29,30].
In the GNEM-DMP registry dataset several cases of cardiac
conduction abnormalities, cardiomyopathy and respiratory
difficulty (including use of CPAP) were identified. The rate of
cardiomyopathy in the registry data set is low (2/137), but
formally higher than in general adult population (1:2500 [31]).
However, considering the low number of observations in the
registry and low statistical power of the analysis we cannot
conclude whether the risk of cardiomyopathy in GNE patients
truly increased.
5. Conclusions
In this initial report from the GNE myopathy DMP-registry,
we have illustrated the successful implementation of an
international registry based on a public-private partnership
model and its versatile use as both a tool for disseminating
information and also for recruitment to clinical trials. Data
showing the disease presentation and progression support
previous, retrospective reports of GNE myopathy as a
slowly progressive disease and contribute to a step-by-step
understanding of the disease progression, and also allow to
quantify and time-stamp these changes. Patient reported
outcomes used in this study showed the longitudinal decline in
mobility, upper extremity function and self-care and may help
to power future studies and support the development of
management guidelines as well as socio-economic assessments
(burden of illness studies). The observed relationships between
phenotype and genotype may help to predict progression of the
disease and support patient stratification in clinical trials
depending upon individual rates of disease progression. Study
limitations such as restrictions of the data collection technique,
small sample size (and therefore low statistical power),
confounding factors (e.g. age at baseline, and gender) allow us
to report these findings as an initial observation, which needs to
be replicated on a larger cohort before conclusions can be
drawn. This is a first report based on the international GNE
myopathy registry, which continues to evolve and collect data
on a large population over a long period of time. To conclude,
the registry is an effective method of data collection and
information dissemination, which can contribute valuable
knowledge and address scientific difficulties in a small and
Fig. 7. Steady decline of GNEM-FAS score in a subset of patient who
completed all four interval history visits over 2 years (n = 16). 24-month score
is significantly lower compared to baseline, ANOVA, p = 0.016.
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multi-ethnic cohort and help translational research in rare
disease.
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